Skip to content

Ligand Pharmaceuticals LGND Professional service fees

Professional service fees at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.6B+96.7%

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's professional service fees.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's professional service fees?
Ligand Pharmaceuticals (LGND) reported professional service fees of $2.74M in Q1 2026.
How has Ligand Pharmaceuticals's professional service fees changed year-over-year?
Ligand Pharmaceuticals's professional service fees decreased by 49.5% year-over-year, from $5.43M to $2.74M.
What is the long-term trend for Ligand Pharmaceuticals's professional service fees?
Over 5 years (2020 to 2025), Ligand Pharmaceuticals's professional service fees has grown at a 15.4% compound annual growth rate (CAGR), from $977K to $2M.